REG - CRISM Therapeutics - Establishment of Scientific Advisory Board

CRISM' TherapeuticsAnnouncement

03/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250603:nRSC1075La&default-theme=true

RNS Number : 1075L  CRISM Therapeutics Corporation  03 June 2025

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No.
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

3 June 2025

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

Establishment of Scientific Advisory Board

 

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs, announces
that it has established a Scientific Advisory Board ("SAB") to provide the
Company with expert guidance as it prepares to submit its Clinical Trial
Application ("CTA") authorisation for ChemoSeed in glioblastoma.

The role of the SAB is to provide the Company with specific guidance on its
upcoming registration grade Phase II clinical trial for irinotecan ChemoSeed
in patients with glioblastoma. Furthermore, the Company can benefit from the
external perspectives which the members of the SAB can bring to steer its
future strategies. Details of the SAB members are as follows:

Garth Cruickshank, PhD, MBBS, FRCS (Ed), FRCS (Eng), FRCS (SN)

Garth Cruickshank is Emeritus Professor of Neurosurgery at the University of
Birmingham. He has worked on hypoxic mechanisms in brain tumour behaviour
using per-operative oxygen electrodes and was the first neurosurgeon to inject
modified live oncolytic HSV1716 into human brain tumours. He has participated
in several interventional glioma clinical trials including HSVtk, and TGFbeta
infusion. He helped develop the NICE Improving Outcomes Guidance (2006) for
Brain Tumours and was the Lead Clinician for 2018 NICE Brain Tumour current
clinical guidelines. He has acted as an advisor for care provider, BSI
Healthcare and a reviewer for the National Institute for Health and Care
Research.

Dr. Vinton Cheng MBBS MRCP PGDip DPhil

Dr. Vinton Cheng is an Associate Clinical Professor and Honorary Consultant in
Medical Oncology at the University of Birmingham with a clinical focus on the
holistic management of adult patients with primary and metastatic brain
tumours, including with the delivery of systemic therapies. Dr Cheng's
research interests are in developing systemic therapy trials for brain tumour
patients and studying the progression of cancer in the brain.

Commenting on the establishment of the SAB, CRISM CEO Andrew Webb said: "We
believe that CRISM has established a strong scientific advisory board, with
both Vinton and Garth highly experienced in the field of neuro-oncology. They
have significant expertise in the field of running successful clinical trials,
regulation and academia and we are fortunate to be able to draw on this as the
Company prepares its CTA authorisation and subsequent phase II clinical trial
for ChemoSeed in glioblastoma."

 

-Ends-

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl                         CRISM@buchanancomms.co.uk
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

 

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the
blood brain barrier, which prevents other treatments from being able to reach
the tumour and be effective.

CRISM is expects to submit a clinical trial application for ChemoSeed
glioblastoma in H2 2025.

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFTMRTMTJMBIA